Division of Amneal Pharmaceuticals LLC
Latest From Impax Pharmaceuticals
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Andrew Mulberg leaves US FDA for Amicus Therapeutics. Ipsen, Iroko, TapImmune make topside changes.
FDA dealt Impax Pharmaceuticals a “complete response” for its extended-release carbidopa/levodopa therapy for spasms suffered by Parkinson’s disease patients, rejecting the drug combo based on unresolved manufacturing issues at the firm’s Hayward, Calif., plant, though Impax has said it will manufacture the product, now called Rytary, exclusively at its Taiwan facility.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Controlled Release
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Amneal Pharmaceuticals LLC
- Senior Management
Michael Nestor, Pres.
Suneel Gupta, PhD, CSO
Shawn Fatholahi, VP, Sales & Mktg.
David Paterson, PhD, VP, Bus. Dev.
- Contact Info
Phone: (510) 240-6000
31047 Genstar Rd.
Hayward, CA 94544
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.